Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects.

Authors:
Li LC; Kan LD.

Journal:
J Ethnopharmacol

Publication Year: 2016

DOI:
10.1016/j.jep.2016.12.042

PMCID:
PMC7127743

PMID:
28038955

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Ethnopharmacol

Abbreviation: J Ethnopharmacol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Social Sciences

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Comparison study of Beninese and Chinese herbal medicines in treating COVID-19.
Houeze EA; Wang Y; Zhou Q and 2 more (2023) - Transparency Score: 4/6
Chemical profiling and unraveling of anti-COVID-19 biomarkers of red sage (Lantana camara L.) culti…
Darwish RS; El-Banna AA; Ghareeb DA and 3 more (2022) - Transparency Score: 2/6
Efficacy and safety of add-on Viola odorata L. in the treatment of COVID-19: A randomized double-bl…
Adel Mehraban MS; Shirzad M; Mohammad Taghizadeh Kashani L and 5 more (2022) - Transparency Score: 4/6
Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhib…
Zhu Y; Han Q; Wang L and 10 more (2022) - Transparency Score: 4/6
Shufeng Jiedu capsule inhibits inflammation and apoptosis by activating A2AAR and inhibiting NF-κB …
Cai J; Wang YL; Sheng XD and 2 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest None of the authors has any conflicts of interest to declare."

Evidence found in paper:

"This study was supported by the National Natural Science Foundation of China (Grant no. 81503129) and Traditional Chinese Medicine Research Project of Zhejiang Province (Grant no. 2013ZB085). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025